A CRISPR/Cas14a-based platform for sensitive and specific single-nucleotide variant detection via short single-strand DNA amplification and split target design.
A new CRISPR-based detection system identifies cancer mutations and genetic variations with extraordinary sensitivity, potentially improving early diagnosis.
Single-nucleotide variant (SNV) detection, including tumor-associated mutation detection and pharmacogenetic genotyping, holds significant clinical value. Experimental results demonstrate that SAST system achieves a Concentration LOD (limit of detection) of 100 aM for target DNA and a MAF (mutant allele frequency) LOD of 0.00001% in simulated samples.
What the study was
- Study design
- Observational Study
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Biosensors & bioelectronics
Why it surfaced
Matched watchlist: Precision oncology and genomic; scored 7/10 based on abstract-level review; design=Observational Study; species=human; flag=PROMISING_PRELIMINARY.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.